Compare ADMA Biologics Inc (ADMA) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs UnitedHealth Group Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while UnitedHealth Group Inc trades at $428.51 (market cap $388.86B). The key difference: UnitedHealth Group Inc is far larger — about 182.6× ADMA Biologics Inc's market cap, and UnitedHealth Group Inc pays a 2.17% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | UNH | |
|---|---|---|
Market Cap | $2.13B | $388.86B |
Sector | Health | Health |
52-Week High | $20.38 | $428.19 |
52-Week Low | $7.60 | $237.77 |
Enterprise Value | $2.20B | $435.55B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UnitedHealth Group (UNH) trades at $417.99, down 1.73% today, but maintains a bullish technical signal with strong moving averages and support near $414. Revenue grew to $447.57B in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
Outlook remains positive with analyst consensus at Buy (82.69%) and a $419.47 price target, though regulatory risks from lawsuits and margin pressures pose challenges. The stock's valuation at a P/E of 31.48 appears rich relative to historical norms, requiring sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
